ANI Pharmaceuticals (NASDAQ:ANIP) SVP Ori Gutwerg Sells 2,060 Shares of Stock

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) SVP Ori Gutwerg sold 2,060 shares of the business’s stock in a transaction dated Tuesday, March 3rd. The stock was sold at an average price of $76.50, for a total value of $157,590.00. Following the sale, the senior vice president directly owned 84,782 shares of the company’s stock, valued at $6,485,823. This represents a 2.37% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link.

ANI Pharmaceuticals Trading Down 1.6%

Shares of NASDAQ ANIP traded down $1.24 during mid-day trading on Thursday, hitting $75.29. The company’s stock had a trading volume of 16,897 shares, compared to its average volume of 451,891. ANI Pharmaceuticals, Inc. has a one year low of $56.71 and a one year high of $99.50. The company’s fifty day simple moving average is $79.92 and its 200-day simple moving average is $86.11. The company has a debt-to-equity ratio of 1.11, a current ratio of 2.71 and a quick ratio of 2.19. The stock has a market cap of $1.69 billion, a price-to-earnings ratio of 22.41 and a beta of 0.52.

Wall Street Analyst Weigh In

ANIP has been the subject of several recent research reports. Weiss Ratings reiterated a “hold (c+)” rating on shares of ANI Pharmaceuticals in a research report on Monday, December 29th. Guggenheim upped their price objective on ANI Pharmaceuticals from $115.00 to $124.00 and gave the company a “buy” rating in a report on Friday, January 16th. Barclays assumed coverage on ANI Pharmaceuticals in a research note on Tuesday, December 9th. They issued an “overweight” rating and a $100.00 target price on the stock. Finally, Zacks Research lowered ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, January 6th. Six research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $103.43.

Institutional Trading of ANI Pharmaceuticals

Hedge funds have recently added to or reduced their stakes in the business. Advisors Asset Management Inc. acquired a new position in ANI Pharmaceuticals in the first quarter valued at about $28,000. Hantz Financial Services Inc. lifted its holdings in shares of ANI Pharmaceuticals by 202.6% during the 3rd quarter. Hantz Financial Services Inc. now owns 354 shares of the specialty pharmaceutical company’s stock valued at $32,000 after purchasing an additional 237 shares in the last quarter. Newbridge Financial Services Group Inc. grew its position in shares of ANI Pharmaceuticals by 200.0% in the 2nd quarter. Newbridge Financial Services Group Inc. now owns 600 shares of the specialty pharmaceutical company’s stock valued at $39,000 after purchasing an additional 400 shares during the period. Kemnay Advisory Services Inc. acquired a new position in shares of ANI Pharmaceuticals in the 4th quarter valued at approximately $48,000. Finally, State of Wyoming bought a new stake in ANI Pharmaceuticals during the 2nd quarter worth approximately $50,000. Institutional investors and hedge funds own 76.05% of the company’s stock.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.